BR0112998A - Derivados de indol úteis para o tratamento de distúrbios do sistema nervoso central (snc); composto; sua utilização; composição farmacêutica e método de tratamento - Google Patents
Derivados de indol úteis para o tratamento de distúrbios do sistema nervoso central (snc); composto; sua utilização; composição farmacêutica e método de tratamentoInfo
- Publication number
- BR0112998A BR0112998A BR0112998-8A BR0112998A BR0112998A BR 0112998 A BR0112998 A BR 0112998A BR 0112998 A BR0112998 A BR 0112998A BR 0112998 A BR0112998 A BR 0112998A
- Authority
- BR
- Brazil
- Prior art keywords
- treatment
- disorders
- compound
- pharmaceutical composition
- nervous system
- Prior art date
Links
- 210000003169 central nervous system Anatomy 0.000 title abstract 3
- 150000001875 compounds Chemical class 0.000 title abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 229940054051 antipsychotic indole derivative Drugs 0.000 title 1
- 150000002475 indoles Chemical class 0.000 title 1
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 abstract 2
- 102000040125 5-hydroxytryptamine receptor family Human genes 0.000 abstract 1
- 108091032151 5-hydroxytryptamine receptor family Proteins 0.000 abstract 1
- 208000019901 Anxiety disease Diseases 0.000 abstract 1
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 abstract 1
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 abstract 1
- 102000015554 Dopamine receptor Human genes 0.000 abstract 1
- 108050004812 Dopamine receptor Proteins 0.000 abstract 1
- 208000019695 Migraine disease Diseases 0.000 abstract 1
- 208000012902 Nervous system disease Diseases 0.000 abstract 1
- 208000025966 Neurological disease Diseases 0.000 abstract 1
- 208000028017 Psychotic disease Diseases 0.000 abstract 1
- 208000010877 cognitive disease Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 239000003446 ligand Substances 0.000 abstract 1
- 206010027599 migraine Diseases 0.000 abstract 1
- 208000020016 psychiatric disease Diseases 0.000 abstract 1
- 201000000980 schizophrenia Diseases 0.000 abstract 1
- 229940076279 serotonin Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Neurology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Anesthesiology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Indole Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA200001123 | 2000-07-21 | ||
| PCT/DK2001/000507 WO2002008223A1 (en) | 2000-07-21 | 2001-07-17 | Indole derivatives useful for the treatment of cns disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR0112998A true BR0112998A (pt) | 2003-06-24 |
Family
ID=8159625
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR0112998-8A BR0112998A (pt) | 2000-07-21 | 2001-07-17 | Derivados de indol úteis para o tratamento de distúrbios do sistema nervoso central (snc); composto; sua utilização; composição farmacêutica e método de tratamento |
Country Status (28)
| Country | Link |
|---|---|
| US (1) | US6743809B2 (sk) |
| EP (1) | EP1305307B1 (sk) |
| JP (1) | JP2004504396A (sk) |
| KR (1) | KR100851793B1 (sk) |
| CN (1) | CN1264838C (sk) |
| AR (1) | AR029858A1 (sk) |
| AT (1) | ATE266024T1 (sk) |
| AU (2) | AU8173801A (sk) |
| BG (1) | BG107528A (sk) |
| BR (1) | BR0112998A (sk) |
| CA (1) | CA2416212C (sk) |
| CZ (1) | CZ301114B6 (sk) |
| DE (1) | DE60103162T2 (sk) |
| EA (1) | EA004749B1 (sk) |
| ES (1) | ES2219554T3 (sk) |
| HR (1) | HRP20030015A2 (sk) |
| HU (1) | HUP0302820A3 (sk) |
| IL (2) | IL153605A0 (sk) |
| IS (1) | IS2172B (sk) |
| MX (1) | MXPA02012927A (sk) |
| NO (1) | NO323799B1 (sk) |
| NZ (1) | NZ523436A (sk) |
| PT (1) | PT1305307E (sk) |
| SK (1) | SK286701B6 (sk) |
| TR (1) | TR200401488T4 (sk) |
| UA (1) | UA73995C2 (sk) |
| WO (1) | WO2002008223A1 (sk) |
| ZA (1) | ZA200300287B (sk) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2545261C (en) | 2003-11-17 | 2013-07-23 | Boehringer Ingelheim International Gmbh | Piperidine-substituted indoles- or heteroderivatives thereof |
| TWI391387B (zh) * | 2004-05-12 | 2013-04-01 | Eisai R&D Man Co Ltd | 具有哌啶環之吲哚衍生物 |
| JP5080450B2 (ja) | 2005-04-30 | 2012-11-21 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 新規なピペリジン置換インドール |
| CA2667547C (en) | 2006-10-27 | 2014-07-29 | Boehringer Ingelheim International Gmbh | Piperidyl-propane-thiol ccr3 modulators |
| CN101486654B (zh) * | 2009-03-04 | 2012-10-10 | 西安近代化学研究所 | 2-甲基-3-硝基苯乙酸合成方法 |
| CN110041318B (zh) * | 2018-01-17 | 2022-07-29 | 中国科学院上海药物研究所 | 一类多巴胺d5受体激动剂及其制备和应用 |
| CN110498789B (zh) * | 2018-05-17 | 2022-04-05 | 上海医药工业研究院 | 芳烷哌啶类衍生物及其在多靶点抗抑郁症中的应用 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2322470A1 (de) * | 1973-05-04 | 1974-11-21 | Boehringer Sohn Ingelheim | Neue indolyl-piperidino-(bzw. 1,2,5,6tetrahydro-pyridyl-)butyrophenone und verfahren zu ihrer herstellung |
| AT332401B (de) * | 1973-11-26 | 1976-09-27 | Roussel Uclaf | Verfahren zur herstellung von neuen (4'-(3''-indolyl)-piperidino)-alkylarylketonderivaten |
| GB8719167D0 (en) | 1987-08-13 | 1987-09-23 | Glaxo Group Ltd | Chemical compounds |
| IE61488B1 (en) * | 1987-08-13 | 1994-11-02 | Glaxo Group Ltd | Indole derivatives |
| JPH08501287A (ja) * | 1992-08-05 | 1996-02-13 | ジョン・ワイス・アンド・ブラザー・リミテッド | アミド誘導体 |
| NZ265269A (en) * | 1993-04-22 | 1996-09-25 | Pfizer Research & Dev Co | Substituted indole derivatives, preparation and medicaments thereof |
| ES2063700B1 (es) * | 1993-04-28 | 1995-07-16 | Vita Invest Sa | Agente activo sobre el sistema nervioso central, proceso para su preparacion y composiciones farmaceuticas que lo contengan. |
| US5576321A (en) * | 1995-01-17 | 1996-11-19 | Eli Lilly And Company | Compounds having effects on serotonin-related systems |
| GB9718712D0 (en) * | 1997-09-03 | 1997-11-12 | Merck Sharp & Dohme | Theraputic Agents |
-
2001
- 2001-07-17 NZ NZ523436A patent/NZ523436A/en unknown
- 2001-07-17 HU HU0302820A patent/HUP0302820A3/hu unknown
- 2001-07-17 HR HR20030015A patent/HRP20030015A2/hr not_active Application Discontinuation
- 2001-07-17 EA EA200300179A patent/EA004749B1/ru not_active IP Right Cessation
- 2001-07-17 ES ES01960182T patent/ES2219554T3/es not_active Expired - Lifetime
- 2001-07-17 CZ CZ20030196A patent/CZ301114B6/cs not_active IP Right Cessation
- 2001-07-17 CA CA002416212A patent/CA2416212C/en not_active Expired - Fee Related
- 2001-07-17 MX MXPA02012927A patent/MXPA02012927A/es active IP Right Grant
- 2001-07-17 BR BR0112998-8A patent/BR0112998A/pt not_active IP Right Cessation
- 2001-07-17 AT AT01960182T patent/ATE266024T1/de not_active IP Right Cessation
- 2001-07-17 IL IL15360501A patent/IL153605A0/xx unknown
- 2001-07-17 UA UA2003010167A patent/UA73995C2/uk unknown
- 2001-07-17 EP EP01960182A patent/EP1305307B1/en not_active Expired - Lifetime
- 2001-07-17 DE DE60103162T patent/DE60103162T2/de not_active Expired - Fee Related
- 2001-07-17 WO PCT/DK2001/000507 patent/WO2002008223A1/en not_active Ceased
- 2001-07-17 CN CNB018151078A patent/CN1264838C/zh not_active Expired - Fee Related
- 2001-07-17 JP JP2002514129A patent/JP2004504396A/ja active Pending
- 2001-07-17 PT PT01960182T patent/PT1305307E/pt unknown
- 2001-07-17 AU AU8173801A patent/AU8173801A/xx active Pending
- 2001-07-17 SK SK203-2003A patent/SK286701B6/sk not_active IP Right Cessation
- 2001-07-17 KR KR1020037000850A patent/KR100851793B1/ko not_active Expired - Fee Related
- 2001-07-17 TR TR2004/01488T patent/TR200401488T4/xx unknown
- 2001-07-17 AU AU2001281738A patent/AU2001281738B2/en not_active Ceased
- 2001-07-20 AR ARP010103457A patent/AR029858A1/es unknown
-
2002
- 2002-12-23 IS IS6663A patent/IS2172B/is unknown
- 2002-12-24 IL IL153605A patent/IL153605A/en not_active IP Right Cessation
-
2003
- 2003-01-10 ZA ZA200300287A patent/ZA200300287B/en unknown
- 2003-01-10 NO NO20030127A patent/NO323799B1/no not_active IP Right Cessation
- 2003-01-17 US US10/347,574 patent/US6743809B2/en not_active Expired - Fee Related
- 2003-02-05 BG BG107528A patent/BG107528A/bg unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0415657A (pt) | derivados de alcanamina de diidrobenzofuranila como agonistas de 5ht2c | |
| BR0214024A (pt) | Derivados de 1,2,4-tiadiazol como moduladores de receptor de melanocortina | |
| SE0303180D0 (sv) | Novel compounds | |
| BR0114552A (pt) | N1- (benzenosulfonil) indóis 2-,3-,4-, 5- substituìdos e seu uso em terapia | |
| MEP45308A (en) | [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia | |
| EA199700156A1 (ru) | Производные индола как антагонисты рецептора 5-нт | |
| SE0201635D0 (sv) | Novel compounds | |
| MA27926A1 (fr) | Derives de quinoline et de quinazoline presentant une affinite vis-a-vis des recepteurs du type 5ht1 | |
| EA200500342A1 (ru) | Гетероциклические замещённые пиперазины для лечения шизофрении | |
| MA31521B1 (fr) | Dérivés de 2,3-dihydrobenzo[1,4] dioxin-2-ylméthyle utilisés en tant qu'antagonistes des alpha2c pour traiter des maladies des systèmes nerveux périphérique et central | |
| TW200510303A (en) | Novel compounds | |
| MX2007013021A (es) | Derivados de benzofuranil-alcanamina y usos de los mismos como agonistas de 5-ht2c. | |
| NO970164D0 (no) | Anvendelse av tiazol- og tiadiazolforbindelser som D3 - dopaminreseptorligander | |
| BRPI0415769A (pt) | alcanaminas de diidrobenzofuranila e composições farmacêuticas contendo-as | |
| BR0311593A (pt) | Derivados de 1-sulfonil-4-aminoalcoxi indol como moduladores de receptor 5-ht6 para tratamento dos distúrbios de snc | |
| IL186777A0 (en) | (3,4-dihydro-quinazolin-2-yl) - (2-aryloxy-ethyl) - amines having an activity on the 5 - ht receptor | |
| DE60322186D1 (de) | 1-arylsulfonyl-3-substituierte indol und indolinederivate verwendbar zur behandlung von erkrankungen des zentralnervensystem | |
| FR2817256B1 (fr) | Derives de l'acides 4-hydroxybutanoique et de son homologue superieur comme ligands des recepteurs du gamma- hydroxybutyrate (ghb), compositions pharmaceutiques les contenant et utilisations pharmaceutiques | |
| BR0112998A (pt) | Derivados de indol úteis para o tratamento de distúrbios do sistema nervoso central (snc); composto; sua utilização; composição farmacêutica e método de tratamento | |
| DE60209362D1 (de) | 3-substituierte chinolin-4-carbonsäureamidderivate als nk-3- und nk-2-rezeptorantagonisten | |
| HRP20010969B1 (en) | Novel piperazinylalkylthiopyrimidine derivatives, | |
| ES2154605A1 (es) | Nuevos derivados mixtos de bencimidazol-arilpiperazina con afinidad por los receptores serotoninergicos 5-ht1a y 5-ht3 | |
| BR0211140A (pt) | Compostos e composições de indóis de hexaidroazepina (4, 5-g) e indolinas como ligantes de receptores 5-ht | |
| BRPI0517955A (pt) | indolizinas substituìdas e derivados como agentes de snc | |
| CA2411412A1 (en) | Indole derivatives useful for the treatment of cns disorders |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE AS 9A E 10A ANUIDADES. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2156 DE 02/05/2012. |